文献速递前列腺癌

RNA原位杂交检测尿液中脱落前列腺癌细胞的新方法

A novel method for detection of exfoliated prostate cancer cells in urine by RNA in situ hybridization.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2020-08-20

本研究探索了使用RNA原位杂交(RISH)检测尿液中脱落前列腺癌细胞的可行性。研究者优化了尿液细胞学标本的采集、处理和靶标检测流程,筛选出NKX3-1和PRAC1作为前列腺来源细胞标记、PCA3作为前列腺恶性肿瘤标记,并在19例前列腺癌患者DRE后尿液中验证了多重RISH assay的分析有效性,发现11例存在前列腺细胞、其中6例前列腺癌细胞阳性。

要点

  • 多重RISH可直观显示并分子表征尿液中单个脱落前列腺细胞。
  • NKX3-1/PRAC1标记前列腺来源细胞,PCA3标记前列腺癌细胞。
  • DRE后尿液RISH检测在前列腺癌患者中显示初步可行性。

核心结论

  • 多重RISH可实现对尿液中单个脱落前列腺细胞的直接可视化和分子表征。
  • 该原理验证研究支持RISH作为前列腺癌检测的潜在非侵入性工具。

研究设计与样本

  • 方法开发、优化和分析评估研究,聚焦尿液中前列腺癌RISH检测。
  • 筛选11个前列腺特异性RNA靶标,选定NKX3-1、PRAC1和PCA3。
  • 在19例确诊前列腺癌患者的DRE后尿液标本中进行初步队列评估。

主要发现

  • 利用加标尿液样本制备的细胞学标本,建立了RISH检测前列腺细胞的分析有效性。
  • 基于NKX3-1、PRAC1和PCA3的多重检测可区分良性与恶性前列腺细胞群体。
  • 19例前列腺癌患者DRE后尿液中,11例检出前列腺细胞,其中6例前列腺癌细胞阳性。

临床怎么用

  • RISH可作为前列腺癌无创检测的潜在方法,但需进一步临床验证。
  • DRE后尿液样本适用于脱落前列腺细胞的分子检测。

局限性

  • 仅为原理验证研究,样本量小(19例),需更大规模验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the current study, we explore the feasibility of detecting exfoliated prostate cancer cells in urine using an RNA in situ hybridization (RISH) assay. We hypothesized that robust and specific labeling of prostate cancer cells could be achieved in post-digital rectal examination (DRE) urine samples using RISH. METHODS: We focused on method development, optimization, and analytical evaluation of RISH-based detection of prostate cancer in urine. We optimized a sample collection, processing, and target detection workflow for urine cytology specimens in conjunction with RNA target detection by RISH. We screened a panel of 11 prostate-specific RNA targets, and selected NKX3-1 and PRAC1 as markers for cells of prostate origin and PCA3 as a marker of prostate malignancy. Following analytical validation of a multiplexed NKX3-1/PRAC1/PCA3 assay, we evaluated whether prostate cancer cells can be detected in a pilot cohort of 19 post-DRE specimens obtained from men diagnosed with prostate cancer. RESULTS: Using cytology specimens prepared from spiked urine samples, we established the analytical validity of the RISH assay for detection and visualization of prostate cells in urine. Cells of prostate origin could be readily and specifically identified and separated into benign and malignant cell populations based on the multiplex test that consisted of markers specific for prostate cells (NKX3-1, PRAC1) and prostate cancer cells (PCA3). Upon evaluation of post-DRE urine from a pilot cohort of prostate cancer patients, we identified 11 samples in which prostate cells were present, 6 of which were also positive for prostate cancer cells. CONCLUSIONS: Multiplex RISH enables the direct visualization and molecular characterization of individual exfoliated prostate cells in urine. This proof-of-principle study provides evidence supporting the application of RISH as a potential noninvasive tool for prostate cancer detection.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Eskra JN, Rabizadeh D, Mangold L, et al. A novel method for detection of exfoliated prostate cancer cells in urine by RNA in situ hybridization. Prostate Cancer Prostatic Dis. 2020. PMID: 32820256. doi:10.1038/s41391-020-00272-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。